期刊： DRUG DISCOVERY TODAY, 2023; 28 (8)
The novel coronavirus crisis caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was a global pandemic. Although various therapeuti......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (9)
Dysregulation of long noncoding RNAs (lncRNAs) contributes to numerous human diseases, including cancers and autoimmune diseases (ADs). Given the impo......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (9)
Adverse drug events (ADEs) are responsible for a significant number of hospital admissions and fatalities. Machine learning models have been developed......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (11)
Elevated endothelin-1 (ET-1) has been implicated in several diseases including preeclampsia, where it causes the induction of hypertension, oxidative ......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (12)
Dysbiosis-associated molecular pathology is significantly involved in developing and perpetuating metabolic disorders, disrupting host energy regulati......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (1)
Flavonoids are an interesting class of biomolecules, which exhibit cancer-inhibitory effects through both chemopreventive and chemotherapeutic activit......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (3)
Osteoarthritis (OA) is characterized by progressive cartilage degeneration. Pharmaceutical intervention remains a main treatment approach. However, dr......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (4)
The FAIR (findable, accessible, interoperable and reusable) principles are data management and stewardship guidelines aimed at increasing the effectiv......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (6)
Epilepsy (EP) is a long-term neurological disorder charac-terized by neuroinflammatory responses, neuronal apop-tosis, imbalance between excitatory an......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (12)
Inflammation and cell death processes positively control the organ homeostasis of an organism. Receptor-interacting protein kinase 1 (RIPK1), a member......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (10)
Glutaminyl cyclase (QC) activity has been identified as a key effector in distinct biological processes. Human glutaminyl-peptide cyclotransferase (QP......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (10)
Rare disease (RD) patients face significant unmet therapeutic needs worldwide. However, orphan drugs approved in the United States, but not approved o......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (1)
Monoclonal antibody products have risen from obscurity in the 1990s to a position that increasingly dominates both revenue generation and patient impa......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (2)
Metabolomics enables the comprehensive and unbiased analysis of metabolites and lipids in biological systems. In conjunction with high-throughput acti......
期刊： DRUG DISCOVERY TODAY, 2023; 28 (6)
Morphoceuticals are a new class of interventions that target the setpoints of anatomical homeostasis for efficient, modular control of growth and form......
